Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LMAT 
LeMaitre Vascular Inc (LMAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LMAT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $104.62
1 Year Target Price $104.62
| 3 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.18% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.97B USD | Price to earnings Ratio 42.24 | 1Y Target Price 104.62 |
Price to earnings Ratio 42.24 | 1Y Target Price 104.62 | ||
Volume (30-day avg) 11 | Beta 0.77 | 52 Weeks Range 71.10 - 108.82 | Updated Date 10/17/2025 |
52 Weeks Range 71.10 - 108.82 | Updated Date 10/17/2025 | ||
Dividends yield (FY) 0.83% | Basic EPS (TTM) 2.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.08% | Operating Margin (TTM) 25.13% |
Management Effectiveness
Return on Assets (TTM) 7.28% | Return on Equity (TTM) 13.81% |
Valuation
Trailing PE 42.24 | Forward PE 34.84 | Enterprise Value 1832922536 | Price to Sales(TTM) 8.38 |
Enterprise Value 1832922536 | Price to Sales(TTM) 8.38 | ||
Enterprise Value to Revenue 7.81 | Enterprise Value to EBITDA 24.84 | Shares Outstanding 22637522 | Shares Floating 20848252 |
Shares Outstanding 22637522 | Shares Floating 20848252 | ||
Percent Insiders 7.8 | Percent Institutions 95.18 |
Upturn AI SWOT
LeMaitre Vascular Inc
Company Overview
History and Background
LeMaitre Vascular Inc. was founded in 1983. The company has grown through product development and acquisitions, focusing on specialized vascular surgery products. Key milestones include expansion into new product categories and global markets.
Core Business Areas
- Cardiovascular: Manufactures and markets devices for the treatment of peripheral vascular disease, cardiovascular, and endovascular diseases. Products include vascular grafts, valvulotomes, shunts, and angioscopes.
Leadership and Structure
George W. LeMaitre serves as Chairman and CEO. The company has a typical corporate structure with functional departments like R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- XenoSure Biologic Patch: A bovine pericardial patch used for vascular reconstruction. Competitors include W.L. Gore and Associates and Baxter International. Market share data is not publicly disclosued but is a significant revenue driver.
- Valvulotomes: Devices used to remove valves in veins for in-situ bypass procedures. They dominate the vein harvest market, a niche market. Competitors include Scanlan International and Integra LifeSciences.
Market Dynamics
Industry Overview
The vascular surgery device market is driven by an aging population, increasing prevalence of vascular disease, and technological advancements. It's a competitive market with large and small players.
Positioning
LeMaitre Vascular is positioned as a specialty vascular device company, focusing on specific niches within the broader market. Their competitive advantage lies in specialized products and a direct sales force.
Total Addressable Market (TAM)
The global vascular surgery market is estimated at USD 10 billion. LeMaitre occupies a smaller, more specialized segment within this TAM, with TAM for their specific products estimated at $3 billion, with high growth in developing nations.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Direct sales force
- Strong brand reputation in niche markets
- History of successful acquisitions
Weaknesses
- Relatively small size compared to major competitors
- Dependence on a limited number of key products
- Higher exposure to single geographic locations
- Stock price is considered expensive relative to earnings.
Opportunities
- Expanding into new geographic markets
- Developing innovative products
- Acquiring complementary technologies
- Increased use of minimally invasive surgery
- Increased market growth in Asia-Pacific
Threats
- Competition from larger medical device companies
- Pricing pressures
- Regulatory changes
- Product liability risks
- Slowing economic growth
Competitors and Market Share
Key Competitors
- W.L. Gore & Associates (Privately Held)
- Medtronic (MDT)
- Becton Dickinson (BDX)
Competitive Landscape
LeMaitre competes with larger companies in some markets but has a strong position in specialized niches. Its focus on innovation and direct sales provides a competitive advantage.
Major Acquisitions
Artegraft, Inc
- Year: 2021
- Acquisition Price (USD millions): 90
- Strategic Rationale: Expanded LeMaitre's product portfolio with biologic vascular grafts.
Growth Trajectory and Initiatives
Historical Growth: LeMaitre Vascular has demonstrated consistent revenue growth through organic sales and acquisitions.
Future Projections: Analysts project continued revenue growth of 5-10% per year over the next 3-5 years, driven by new product launches and geographic expansion.
Recent Initiatives: Recent initiatives include expansion into new product categories and strategic acquisitions.
Summary
LeMaitre Vascular is a specialty vascular device company with a focus on niche markets and a history of growth through product development and acquisitions. The company's strengths include a specialized product portfolio, direct sales force, and strong brand reputation. Key opportunities include expanding into new geographic markets, developing innovative products, and strategic acquisitions. The main thing to keep an eye on is competition from bigger players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Analyst Reports, Industry Research Reports, Market Data Platforms
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LeMaitre Vascular Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2006-10-19 | Chairman & CEO Mr. George W. LeMaitre | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 651 | Website https://www.lemaitre.com |
Full time employees 651 | Website https://www.lemaitre.com | ||
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.